科迪亚克科学
估值 各估值倍数与自身5年区间的对比
同业对比 Biotechnology
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 科迪亚克科学 (KOD) | 5.39B | -20.47 | 88.22 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 126.66B | 29.11 | 6.26 | 0.00% |
| Moderna (MRNA) | 87.04B | -27.32 | 12.87 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 81.41B | 19.57 | 2.57 | 0.46% |
| argenx SE (ARGX) | 51.51B | 31.21 | 6.12 | 0.00% |
| BeiGene (ONC) | 41.96B | 65.32 | 8.11 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价高于晨星合理价值估算32.8%。
合理价值
Kodiak Sciences Inc earns a 2-star quantitative star rating, indicating our belief that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 63% premium over our quantitative fair value estimate of $57.64 per share; however, this estimate should be taken with a pinch of salt due to its extreme uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The firm's valuation metrics decrease our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 1.0% sits in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.
The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -3.5%, a core component of profitability, falls in the bottom 20% compared with global peers. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
经济护城河
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
作者:Quantitative Equity Report
报价时间 2026-10-16 20:02:27 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
科迪亚克科学 讨论区 0 条评论